Flag of the European Union EU Clinical Trials Register Help

Clinical trials for sanofi

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,200 result(s) found for: sanofi. Displaying page 25 of 110.
    «« First « Previous 21  22  23  24  25  26  27  28  29  Next» Last»»
    EudraCT Number: 2013-002945-12 Sponsor Protocol Number: EFC12619 Start Date*: 2014-11-12
    Sponsor Name:Sanofi-aventis recherche et développement
    Full Title: Six-month, Randomized, Open-label, Parallel-group Comparison of SAR342434 to Humalog® in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine, with a 6-month Safety Extension Pe...
    Medical condition: Type1-Diabetes
    Disease: Version SOC Term Classification Code Term Level
    17.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-000585-61 Sponsor Protocol Number: ALID02003 Start Date*: 2015-05-18
    Sponsor Name:Genzyme, a Sanofi Company
    Full Title: A Multicenter, Multinational, Open-Label Study of Anti-Laronidase Antibody Formation and Urinary GAG Levels in Patients with Mucopolysaccaridosis I (MPS I) Being Treated with Aldurazyme® (laronidase)
    Medical condition: Mucopolysaccharidosis I Hurler's Syndrome Hurler-Scheie Syndrome Scheie's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10056886 Mucopolysaccharidosis I PT
    Population Age: Infants and toddlers, Children, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004637-47 Sponsor Protocol Number: EFC6132,HMR3647B/3002 Start Date*: 2015-03-17
    Sponsor Name:Sanofi-aventis
    Full Title: Multinational, Randomized, Double-Blind, Double-Dummy, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 25mg/kg od Versus 5 Days Azithromycin 10 mg/kg od Followed by 5 ...
    Medical condition: Otitis Media, Suppurative Otitis Media, Purulent
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10033092 Otitis media suppurative LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004644-35 Sponsor Protocol Number: PKD10491 Start Date*: 2015-03-17
    Sponsor Name:Sanofi-aventis
    Full Title: Single dose, open label safety, tolerability, pharmacokinetic and pharmacodynamic evaluation of three different eplivanserin doses in children aged 6-17 years with insomnia of various origins
    Medical condition: Sleep Initiation and Maintenance Disorders
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10040984 Sleep disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-004339-21 Sponsor Protocol Number: MSC12665 Start Date*: 2014-05-25
    Sponsor Name:sanofi-aventis Recherche & Développement
    Full Title: A Multicenter, Randomized, Open-Label, Parallel-Group Usability Study Of The Sarilumab Auto-Injector Device And A Prefilled Syringe In Patients With Moderate To Severe Active Rheumatoid Arthritis W...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002308-15 Sponsor Protocol Number: PR001 Start Date*: 2013-11-11
    Sponsor Name:Guys & St. Thomas' NHS Foundation Trust
    Full Title: A phase I/II dose finding study evaluating the safety and tolerability of CAPecitabine and AflIbercept in patients with unresectable metasTAtic colorectaL cancer deemed unsuitable for doublet/ trip...
    Medical condition: Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-002309-36 Sponsor Protocol Number: PDY15010 Start Date*: 2018-02-21
    Sponsor Name:SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT
    Full Title: A randomized, double-blind, parallel-group, 2-treatment multiple dose study to assess the intestinal, metabolic and cardiovascular effects of an 8 weeks treatment with sotagliflozin QD as compared ...
    Medical condition: Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000697-35 Sponsor Protocol Number: AGAL19412 Start Date*: 2015-04-24
    Sponsor Name:Genzyme, a Sanofi Company
    Full Title: Evaluation of Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta (The INFORM Study)
    Medical condition: Fabry Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004646-98 Sponsor Protocol Number: TRICA_L_04286 Start Date*: 2015-03-17
    Sponsor Name:Sanofi
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Pharmacodynamic Effect of a 6-week Treatment With Triamcinolone Acetonide Aqueous Nasal Spray 110 μg...
    Medical condition: Rhinitis, Allergic, Perennial and/or Seasonal
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004645-27 Sponsor Protocol Number: XRG5029C_3503 Start Date*: 2015-03-17
    Sponsor Name:Sanofi
    Full Title: A randomized, multicenter, double-blind, placebo-controlled, parallel group study of the 12 month effect of treatment with once daily triamcinolone acetonide (NASACORT® AQ Nasal Spray 110 μg) on th...
    Medical condition: Rhinitis, Allergic, Perennial
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-001163-30 Sponsor Protocol Number: ALID02307 Start Date*: 2015-05-11
    Sponsor Name:Genzyme, a Sanofi Company
    Full Title: A trial of antigen-specific immune tolerance induction in mucopolysaccharidosis I (MPS I) patients initiating enzyme replacement therapy with Aldurazyme® (laronidase)
    Medical condition: Mucopolysaccharidosis I
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10056886 Mucopolysaccharidosis I PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-005026-39 Sponsor Protocol Number: QHD04 Start Date*: 2019-02-01
    Sponsor Name:Sanofi Pasteur Inc
    Full Title: Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 months to 17 Years of Age
    Medical condition: Prevention of influenza infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-007026-19 Sponsor Protocol Number: LANTU_L_04211 Start Date*: 2009-04-24
    Sponsor Name:Aventis Pharma Ltd trading as sanofi-aventis
    Full Title: COMPARISON OF A BASAL PLUS ONE INSULIN REGIMEN (INSULIN GLARGINE/INSULIN GLULISINE) WITH A BIPHASIC INSULIN REGIMEN (INSULIN ASPART/INSULIN ASPART PROTAMINE 30/70) IN TYPE 2 DIABETES PATIENTS FOLLO...
    Medical condition: Type II diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000516-32 Sponsor Protocol Number: LANTU_C_02761 Start Date*: 2008-08-04
    Sponsor Name:sanofi aventis Groupe
    Full Title: Superiority study of insulin glargine over sitagliptin in insulin-naïve patients with type 2 diabetes treated with metformin and not adequately controlled
    Medical condition: Type 2 diabetes treated with metformin and not adequately controlled
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) PT (Completed) AT (Completed) ES (Completed) GB (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-004519-31 Sponsor Protocol Number: ENTERL08784 Start Date*: 2019-01-31
    Sponsor Name:Sanofi
    Full Title: Randomized, placebo-controlled, clinical trial to evaluate the efficacy of probiotic Bacillus clausii in the treatment of pediatric patients with irritable bowel syndrome
    Medical condition: Irritable bowel syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-003529-17 Sponsor Protocol Number: ARCADIA Start Date*: 2008-11-17
    Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI
    Full Title: A PROSPECTIVE, RANDOMIZED, OPEN LABEL, BLINDED END-POINT (PROBE) TRIAL TO EVALUATE WHETHER, AT COMPARABLE BLOOD PRESSURE CONTROL, ACE INHIBITOR THERAPY MORE EFFECTIVELY THAN NON RAS INHIBITOR THERA...
    Medical condition: End stage renal disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10029151 Nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003557-21 Sponsor Protocol Number: LixiBrain01 Start Date*: 2019-02-06
    Sponsor Name:University Hospital Tuebingen
    Full Title: Effect of insulin glargine and lixisenatide versus insulin glargine on brain insulin sensitivity in patients with type 2 diabetes
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003793-94 Sponsor Protocol Number: EFC5574 Start Date*: 2006-10-20
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: An Eight-Week, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled Study, with Escitalopram as an Active Control, to Evaluate the Efficacy, Safety and Tolerability of a Saredut...
    Medical condition: to Evaluate the Efficacy, Safety and Tolerability of a Saredutant 100 mg Dose Once Daily, in Elderly Patients with Major Depressive Disorder (MDD)
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002416-85 Sponsor Protocol Number: EFC12261 Start Date*: 2012-03-21
    Sponsor Name:sanofi-aventis Recherche et Développement
    Full Title: A 24-week, open-label, randomized, 2-arm parallel group, multinational, multi-center clinical trial to compare the efficacy and safety of lixisenatide injected prior to the main meal of the day ver...
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2007-001211-33 Sponsor Protocol Number: EFC10339 Start Date*: 2007-06-20
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: International randomized study to evaluate the addition of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) vs. cisplatin-5-fluorouracil (CF) in the induction treatment of nasopharyng...
    Medical condition: Children and adolescents newly diagnosed with NPC with measurable disease T2-T4 any NM, of <18 years of age at the time of diagnosis. ---------- Niños y adolescentes recien diagnosticados con CNF c...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028793 Nasopharyngeal carcinoma LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) GR (Prematurely Ended) FR (Completed) IT (Completed) DE (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 21  22  23  24  25  26  27  28  29  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 22:32:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA